OBJECTIVE: The HepatAssist liver support system is an extracorporeal porcine hepatocyte-based bioartificial liver (BAL). The safety and efficacy of the BAL were evaluated in a prospective, randomized, controlled, multicenter trial in patients with severe acute liver failure. SUMMARY BACKGROUND DATA: In experimental animals with acute liver failure, we demonstrated beneficial effects of the BAL. Similarly, Phase I trials of the BAL in acute liver failure patients yielded promising results. METHODS: A total of 171 patients (86 control and 85 BAL) were enrolled. Patients with fulminant/subfulminant hepatic failure and primary nonfunction following liver transplantation were included. Data were analyzed with and without accounting for the following confounding factors: liver transplantation, time to transplant, disease etiology, disease severity, and treatment site. RESULTS: For the entire patient population, survival at 30 days was 71% for BAL versus 62% for control (P = 0.26). After exclusion of primary nonfunction patients, survival was 73% for BAL versus 59% for control (n = 147; P = 0.12). When survival was analyzed accounting for confounding factors, in the entire patient population, there was no difference between the 2 groups (risk ratio = 0.67; P = 0.13). However, survival in fulminant/subfulminant hepatic failure patients was significantly higher in the BAL compared with the control group (risk ratio = 0.56; P = 0.048). CONCLUSIONS: This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.
RCT Entities:
OBJECTIVE: The HepatAssist liver support system is an extracorporeal porcine hepatocyte-based bioartificial liver (BAL). The safety and efficacy of the BAL were evaluated in a prospective, randomized, controlled, multicenter trial in patients with severe acute liver failure. SUMMARY BACKGROUND DATA: In experimental animals with acute liver failure, we demonstrated beneficial effects of the BAL. Similarly, Phase I trials of the BAL in acute liver failurepatients yielded promising results. METHODS: A total of 171 patients (86 control and 85 BAL) were enrolled. Patients with fulminant/subfulminant hepatic failure and primary nonfunction following liver transplantation were included. Data were analyzed with and without accounting for the following confounding factors: liver transplantation, time to transplant, disease etiology, disease severity, and treatment site. RESULTS: For the entire patient population, survival at 30 days was 71% for BAL versus 62% for control (P = 0.26). After exclusion of primary nonfunction patients, survival was 73% for BAL versus 59% for control (n = 147; P = 0.12). When survival was analyzed accounting for confounding factors, in the entire patient population, there was no difference between the 2 groups (risk ratio = 0.67; P = 0.13). However, survival in fulminant/subfulminant hepatic failurepatients was significantly higher in the BAL compared with the control group (risk ratio = 0.56; P = 0.048). CONCLUSIONS: This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.
Authors: E Morsiani; J Rozga; H C Scott; L T Lebow; A D Moscioni; L B Kong; M F McGrath; A A Demetriou Journal: ASAIO J Date: 1995 Apr-Jun Impact factor: 2.872
Authors: A J Ellis; R D Hughes; J A Wendon; J Dunne; P G Langley; J H Kelly; G T Gislason; N L Sussman; R Williams Journal: Hepatology Date: 1996-12 Impact factor: 17.425
Authors: Didier Samuel; Philippe Ichai; Cyrille Feray; Faouzi Saliba; Daniel Azoulay; Jean Louis Arulnaden; Pierre Debat; Michelle Gigou; René Adam; Alain Bismuth; Denis Castaing; Henri Bismuth Journal: Transplantation Date: 2002-01-27 Impact factor: 4.939
Authors: F D Watanabe; C J Mullon; W R Hewitt; N Arkadopoulos; E Kahaku; S Eguchi; T Khalili; W Arnaout; C R Shackleton; J Rozga; B Solomon; A A Demetriou Journal: Ann Surg Date: 1997-05 Impact factor: 12.969
Authors: S P Horslen; J M Hammel; L W Fristoe; J A Kangas; D S Collier; D L Sudan; A N Langnas; R S Dixon; E D Prentice; B W Shaw; I J Fox Journal: Transplantation Date: 2000-11-27 Impact factor: 4.939
Authors: Yue Yu; James E Fisher; Joseph B Lillegard; Brian Rodysill; Bruce Amiot; Scott L Nyberg Journal: Liver Transpl Date: 2012-01 Impact factor: 5.799
Authors: Yi Li; Harvey S Chen; Mohammed Shaheen; Dong Jin Joo; Bruce P Amiot; Piero Rinaldo; Scott L Nyberg Journal: Xenotransplantation Date: 2019-04-10 Impact factor: 3.907